| Not Yet Recruiting | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPAR NCT07489495 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcino NCT07500831 | Qilu Hospital of Shandong University | N/A |
| Recruiting | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415 | Pfizer | Phase 1 / Phase 2 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs- NCT06222593 | State University of New York at Buffalo | Phase 1 / Phase 2 |
| Recruiting | Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhance NCT07166445 | Peking University First Hospital | — |
| Recruiting | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527 | Jinling Hospital, China | — |
| Recruiting | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma NCT05287945 | Oncorena AB | Phase 1 / Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Recruiting | Autologous Dendritic Cell Vaccine in Kidney Cancer NCT05127824 | Jodi Maranchie | Phase 2 |
| Recruiting | Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells NCT06194669 | IRCCS San Raffaele | — |
| Terminated | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumor NCT05462873 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Receive NCT05745142 | Pfizer | — |
| Recruiting | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall I NCT05589207 | Peking University Third Hospital | — |
| Unknown | Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma NCT05790122 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | — |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Sy NCT05534789 | Pfizer | — |
| Recruiting | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors NCT05865730 | EverImmune | Phase 2 |
| Active Not Recruiting | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembr NCT05899049 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants NCT05239728 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Rena NCT04895748 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neo NCT05104905 | Faron Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Completed | An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants NCT04941768 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Active Not Recruiting | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma NCT04387500 | West China Hospital | Phase 2 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) NCT04846920 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembr NCT04736706 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell NCT04586231 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) NCT04626518 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal NCT04626479 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Unknown | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors NCT04602702 | Sunnybrook Health Sciences Centre | — |
| Terminated | Mobile Intervention - Physical Activity in Cancer Treatment NCT03671304 | University of Texas Southwestern Medical Center | N/A |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) NCT04489771 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subject NCT04496089 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Terminated | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With A NCT04338269 | Hoffmann-La Roche | Phase 3 |
| Unknown | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies NCT04544748 | AO GENERIUM | Phase 1 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482- NCT04195750 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer NCT04060537 | CCTU- Cancer Theme | — |
| Completed | REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA NCT03916458 | Pfizer | — |
| Unknown | Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-re NCT04113486 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinom NCT04028245 | Columbia University | EARLY_Phase 1 |
| Withdrawn | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surg NCT03943771 | University Hospital, Bordeaux | N/A |
| Completed | Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospect NCT05729763 | San Luigi Gonzaga Hospital | — |
| Withdrawn | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer NCT03111901 | William Grosh, MD | Phase 1 / Phase 2 |
| Terminated | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors NCT03685591 | Pfizer | Phase 1 |
| Completed | a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy NCT03900364 | Salzburger Landeskliniken | N/A |
| Terminated | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma NCT02782715 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Completed | "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC" NCT03538717 | Pfizer | — |
| Completed | KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers NCT04295174 | Odense University Hospital | — |
| Completed | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing NCT03109015 | Duke University | Phase 2 |
| Terminated | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With NCT03165721 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Savolitinib vs. Sunitinib in MET-driven PRCC. NCT03091192 | AstraZeneca | Phase 3 |
| Completed | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localiz NCT03138512 | Bristol-Myers Squibb | Phase 3 |
| Completed | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types NCT03012581 | UNICANCER | Phase 2 |
| Completed | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC NCT03136627 | AVEO Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in NCT02978118 | Duke University | — |
| Terminated | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors NCT02952989 | Seagen Inc. | Phase 1 |
| Completed | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma NCT02917772 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma NCT02729194 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Completed | Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma NCT02732665 | Jens Nielsen | — |
| Completed | Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma NCT02732652 | Chalmers University of Technology | — |
| Completed | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Ca NCT02627963 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Withdrawn | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immuno NCT03226236 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Terminated | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer NCT02560012 | The University of Texas Health Science Center, Houston | Phase 2 |
| Completed | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors NCT02700568 | Kidney Cancer Research Bureau | Phase 2 |
| Terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer NCT02543645 | Celldex Therapeutics | Phase 1 |
| Completed | Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Re NCT02454478 | Eisai Co., Ltd. | Phase 1 |
| Unknown | Intraoperative Dual-modality Imaging in Renal Cell Carcinoma NCT02497599 | Radboud University Medical Center | Phase 1 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma NCT02386111 | Celldex Therapeutics | Phase 1 |
| Unknown | Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma NCT02417194 | Seoul National University Hospital | — |
| Completed | Follow up After Cryoablation of Small Renal Masses. NCT02411968 | Radboud University Medical Center | — |
| Unknown | Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions NCT01141816 | St. Joseph's Healthcare Hamilton | N/A |
| Withdrawn | Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer NCT01353794 | Bayer | — |
| Completed | Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses NCT02248389 | Indiana University | Phase 1 |
| Unknown | Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients NCT02324803 | Southern China Urology Cancer Consortium | Phase 2 |
| Completed | Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Me NCT02334709 | University Hospital, Ghent | Phase 1 / Phase 2 |
| Completed | Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carci NCT01982097 | Bayer | — |
| Completed | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) NCT02014636 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of rSIFN-co in Subjects With Advanced Solid Tumors NCT02387307 | Sichuan Huiyang Life Science and Technology Corporation | Phase 1 |
| Terminated | RGD-PET-CT in Cancer Angiogenesis NCT01492192 | Oxford University Hospitals NHS Trust | Phase 2 |
| Completed | Sorafenib in Elderly mRCC NCT01728948 | Bayer | — |
| Terminated | Imaging Studies of Kidney Cancer Using 18F-VM4-037 NCT01712685 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced NCT01649778 | Novartis Pharmaceuticals | — |
| Completed | A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Ren NCT01672775 | Agensys, Inc. | Phase 1 |
| Completed | Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma NCT01508364 | Bayer | — |
| Terminated | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma NCT01545817 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma NCT06111560 | Sun Yat-sen University | — |
| Completed | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma NCT01521715 | iOMEDICO AG | Phase 4 |
| Withdrawn | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. NCT01441388 | Pfizer | Phase 1 |
| Completed | Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting NCT01557127 | Bayer | — |
| Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. NCT01398306 | University Medical Center Groningen | — |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Completed | Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma NCT01339975 | University Hospital, Bordeaux | — |
| Completed | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insure NCT01381601 | GlaxoSmithKline | — |
| Completed | Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors NCT01334073 | University Hospital, Bordeaux | Phase 1 |
| Completed | Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus NCT01328691 | Seoul National University Hospital | — |
| Completed | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insure NCT01381614 | GlaxoSmithKline | — |
| Completed | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Tem NCT01367457 | Pfizer | — |
| Terminated | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based The NCT01195649 | Bayer | — |
| Completed | Cardiovascular and Torsades de Pointes Monitoring for Pazopanib NCT01446224 | GlaxoSmithKline | — |
| Completed | Hepatic Monitoring for Pazopanib NCT01449825 | GlaxoSmithKline | — |
| Completed | Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers NCT01107509 | St. Joseph's Healthcare Hamilton | N/A |
| Completed | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) NCT01221506 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Completed | Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Ce NCT01147822 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer NCT01064310 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A40 NCT01056263 | Pfizer | — |
| Completed | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. NCT01024920 | Boehringer Ingelheim | Phase 2 |
| Completed | Sunitinib in Metastatic Renal Cancer NCT01034878 | Istituto Clinico Humanitas | Phase 2 |
| Completed | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma NCT00992121 | GlaxoSmithKline | Phase 1 |
| Completed | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma NCT01021059 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma NCT01015911 | Seagen Inc. | Phase 1 |
| Completed | Regulatory Post Marketing Surveillance Study on Nexavar® NCT01012011 | Bayer | — |
| Completed | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer NCT00835978 | Pfizer | Phase 2 |
| Completed | Study Evaluating Renal Cell Carcinoma Risk Factors NCT00927043 | Pfizer | — |
| Completed | A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanc NCT00923481 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEG111485: A QTc Study of Pazopanib NCT00861029 | GlaxoSmithKline | Phase 1 |
| Terminated | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer NCT00816686 | Astellas Pharma Inc | Phase 1 |
| Completed | Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging NCT00842790 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma NCT00720941 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastat NCT00706706 | Pfizer | Phase 4 |
| Completed | microRNA Expression in Renal Cell Carcinoma NCT00743054 | Sun Yat-sen University | — |
| Withdrawn | An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progr NCT00538772 | Kim Chi | — |
| Completed | Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment NCT00716625 | Pfizer | — |
| Completed | A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® NCT00771147 | Bayer | — |
| Completed | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients NCT00891475 | Kidney Cancer Research Bureau | Phase 1 / Phase 2 |
| Terminated | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. NCT00622479 | Bayer | Phase 1 |
| Completed | A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable R NCT00664326 | Bayer | Phase 2 |
| Completed | Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan NCT01411423 | Bayer | — |
| Terminated | A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment NCT00678288 | Bayer | Phase 2 |
| Completed | Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program NCT01412671 | Bayer | — |
| Completed | Sorafenib Dose Escalation in Renal Cell Carcinoma NCT00618982 | Bayer | Phase 2 |
| Completed | Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) NCT00569946 | Pfizer | Phase 2 |
| Completed | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer NCT00854620 | Stanford University | Phase 2 |
| Completed | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell NCT00502307 | AVEO Pharmaceuticals, Inc. | Phase 2 |
| Completed | Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI NCT00537056 | Stanford University | N/A |
| Completed | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors NCT00516672 | GlaxoSmithKline | Phase 1 |
| Completed | Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Ther NCT00529802 | University of Chicago | Phase 2 |
| Completed | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 NCT00478725 | GlaxoSmithKline | Phase 1 |
| Terminated | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC NCT00522249 | The Methodist Hospital Research Institute | Phase 1 / Phase 2 |
| Completed | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma NCT00422786 | Thallion Pharmaceuticals | Phase 2 |
| Completed | Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer NCT00448149 | The Methodist Hospital Research Institute | Phase 1 / Phase 2 |
| Completed | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Ba NCT00591188 | Kidney Cancer Research Bureau | Phase 2 |
| Completed | Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma NCT00372853 | AstraZeneca | Phase 1 |
| Completed | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC NCT00496301 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Completed | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma NCT00389285 | ZymoGenetics | Phase 1 / Phase 2 |
| Terminated | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer NCT00440973 | The Methodist Hospital Research Institute | Phase 2 |
| Completed | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients NCT00363194 | GlaxoSmithKline | Phase 1 |
| Completed | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma NCT00356460 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer NCT00338884 | Pfizer | Phase 2 |
| Completed | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer NCT00387764 | GlaxoSmithKline | Phase 3 |
| Terminated | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib NCT00352859 | Bayer | Phase 4 |
| Completed | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes NCT00401583 | GlaxoSmithKline | Phase 1 |
| Completed | Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar NCT00895674 | Bayer | — |
| Completed | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) NCT00726323 | GlaxoSmithKline | Phase 2 |
| Completed | Study To Assess Long Term Safety Of Pazopanib NCT00387205 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer NCT00445523 | The Methodist Hospital Research Institute | Phase 2 |
| Completed | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma NCT00334282 | GlaxoSmithKline | Phase 3 |
| Completed | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer NCT00282048 | Pfizer | Phase 2 |
| Terminated | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation NCT00698685 | University of Arizona | Phase 2 |
| Completed | Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Rena NCT00267748 | Pfizer | Phase 2 |
| Completed | Study of SU011248 in Patients With Advanced Kidney Cancer NCT00254540 | Pfizer | Phase 2 |
| Completed | Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) NCT00586105 | Bayer | Phase 3 |
| Completed | Long-term Extension From RCC Phase II (11515) NCT00586495 | Bayer | Phase 2 |
| Completed | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer NCT00445042 | The Methodist Hospital Research Institute | Phase 2 |
| Terminated | Research Study for Patients With Metastatic Renal Cell Carcinoma NCT00110344 | Bayer | Phase 2 |
| Completed | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma NCT00325507 | Oxford BioMedica | Phase 2 |
| Completed | An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to Fir NCT00492986 | Bayer | Phase 3 |
| Completed | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma NCT00244764 | GlaxoSmithKline | Phase 2 |
| Terminated | ATN-161 in Advanced Renal Cell Cancer NCT00131651 | Attenuon | Phase 2 |
| Approved For Marketing | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carc NCT00130897 | Pfizer | — |
| Completed | Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma NCT00111020 | Bayer | Phase 3 |
| Completed | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell C NCT00117637 | Bayer | Phase 2 |
| Completed | Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer NCT00446368 | The Methodist Hospital Research Institute | Phase 2 |
| Terminated | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma NCT00523640 | University of Chicago | Phase 2 |
| Completed | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma NCT00256880 | GlaxoSmithKline | Phase 2 |
| Completed | SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma NCT00089648 | Pfizer | Phase 2 |
| Completed | BAY43-9006 Phase II Study for Renal Cell Carcinoma NCT00661375 | Bayer | Phase 2 |
| Completed | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma NCT00113529 | Pfizer | Phase 1 / Phase 2 |
| Completed | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients NCT00158782 | GlaxoSmithKline | Phase 1 |
| Completed | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma NCT00095186 | Agennix | Phase 2 |
| Completed | SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcino NCT00083889 | Pfizer | Phase 3 |
| Completed | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer NCT00083941 | Oxford BioMedica | Phase 2 |
| Completed | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study Wi NCT00106301 | Celgene | Phase 2 |
| Completed | A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcin NCT00077974 | Pfizer | Phase 2 |
| Completed | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer NCT00073307 | Bayer | Phase 3 |
| Completed | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma NCT00265135 | Centocor, Inc. | Phase 1 / Phase 2 |
| Suspended | Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Rena NCT00065572 | AstraZeneca | Phase 2 |
| Completed | Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma NCT00065468 | Pfizer | Phase 3 |
| Completed | A Research Study for Patients With Metastatic Renal Cell Carcinoma NCT00106613 | Celgene | Phase 2 |
| Completed | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma NCT00073125 | Abbott | Phase 2 |
| Completed | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney NCT00050323 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) NCT00043368 | Pfizer | Phase 2 |
| Completed | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer NCT00079612 | Bayer | Phase 2 |
| Completed | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma NCT00059735 | Eisai Inc. | Phase 2 |
| Completed | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma NCT00056173 | Aptose Biosciences Inc. | Phase 1 / Phase 2 |
| Completed | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer NCT00043407 | Pfizer | Phase 1 / Phase 2 |
| Completed | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma NCT00044564 | Bayer | Phase 2 |
| Terminated | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer NCT00158886 | GlaxoSmithKline | Phase 1 |
| Completed | Detection of Renal Malignancy of Complicated Renal Cysts NCT01087060 | Seoul National University Hospital | — |
| Completed | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. NCT00502034 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 |
| Completed | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 NCT00001383 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer NCT00134186 | Pharmacyclics LLC. | Phase 2 |
| Withdrawn | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) NCT02962804 | University of Kansas Medical Center | Phase 2 |